



AUDIT, RESEARCH AND GUIDELINE UPDATE

Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia

Chamira Rodrigo,¹ Tricia M McKeever,² Mark Woodhead,³ Wei Shen Lim,¹
on behalf of the British Thoracic Society

► Additional supplementary data are published online only. To view this file please visit the journal online (<http://dx.doi.org/10.1136/thoraxjnl-2012-202296>)

¹Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK

²Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK

³Department of Respiratory Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK

Correspondence to

Dr Chamira Rodrigo,
Department of Respiratory
Medicine, City Campus,
Nottingham University
Hospitals NHS Trust,
Nottingham NG51PB, UK,
chamira@doctors.org.uk

Received 18 June 2012
Accepted 21 September 2012
Published Online First
16 October 2012



► <http://dx.doi.org/10.1136/thoraxjnl-2012-202296>

To cite: Rodrigo C, McKeever TM, Woodhead M, et al. *Thorax* 2013;**68**:493–495.

ABSTRACT

The benefits of β -lactam/macrolide combination therapy over β -lactam therapy alone for the treatment of hospitalised community-acquired pneumonia (CAP) in relation to pneumonia severity are uncertain. We studied 5240 adults hospitalised with CAP from 72 secondary care trusts across England and Wales. The overall 30-day inpatient (IP) death rate was 24.4%. Combination therapy was prescribed in 3239 (61.8%) patients. In a multivariable model, combination therapy was significantly associated with lower 30-day IP death rate in patients with moderate-severity CAP (adjusted OR 0.54, 95% CI 0.41 to 0.72) and high-severity CAP (adjusted OR 0.76, 95% CI 0.60 to 0.96) but not low-severity CAP.

BACKGROUND

For patients hospitalised with moderate-severity and high-severity CAP, national guidelines recommend empirical combination antibiotic therapy comprising β -lactam and macrolide antibiotics.¹ In some CAP observational cohort studies, macrolide and β -lactam combination therapy has been associated with a lower death rate compared with single-agent antibiotic therapy,² while other studies have reported no differences. A meta-analysis of studies comparing macrolide-based regimens with other treatment regimens (not just single-agent β -lactam therapy) found a reduction in death rate with macrolide use;³ this benefit was felt to be due to guideline concordance rather than antibiotic choice. This uncertain evidence base may partially explain the relatively poor adherence to CAP antibiotic recommendations observed by some investigators. Concerns that broad-spectrum antibiotics promote antimicrobial resistance, medication side effects, cost and nosocomial infections may also limit adherence.

Beginning in 2009, the British Thoracic Society (BTS) conducted the largest national audit of adult CAP management in the UK.⁴ These data were analysed to determine the 'real-world' variation in the use of single versus combination antibiotic therapy in CAP, and whether observed differences in antibiotic use are related to clinical outcomes stratified by pneumonia severity.

METHOD

All trusts across England and Wales were invited to participate in the BTS adult CAP national audit.

Sites were asked to include consecutive immuno-competent adults hospitalised with CAP during the periods 1 December 2009–31 January 2010 and 1 December 2010–31 January 2011. Inclusion criteria were age over 16 years, new infiltrates on admission chest x-ray (CXR) consistent with CAP, symptoms suggestive of a lower respiratory tract infection and treatment given as for CAP. Patients previously discharged from hospital within 10 days of admission were excluded. Following admission, patients were treated at the discretion of the admitting clinical team and data entered anonymously using a secure web-based system. The audit protocol was approved by the BTS Professional and Operational Standards Committee which determined that ethical approval was not required for the conduct of the audit.

For this analysis, patients who received either empirical single-agent therapy with β -lactam antibiotics (defined as any penicillin or cephalosporin antibiotic) or combination therapy with β -lactam and macrolide (defined as erythromycin, clarithromycin or azithromycin) antibiotics were considered. Patients who received other classes of antibiotics such as fluoroquinolones, either alone or in combination with β -lactam or macrolide antibiotics, were excluded. The primary outcome measure was 30-day in-patient (IP) death rate. Secondary outcome measures were length of stay (LOS), intensive care unit (ICU) admission, need for mechanical ventilation (MV), need for inotropic support (INS), time to death and 30-day readmission.

Statistical analysis

Analyses were performed using SPSS V20.0. Pearson's χ^2 test was used to compare categorical variables, perform univariate analyses and generation of ORs and 95% CIs. Mann–Whitney U test was used to compare non-parametric continuous variables. The association between combination antibiotic therapy and 30-day IP death rate was examined using a logistic regression model adjusting for the following variables: age, sex, binary variables within the CURB65 pneumonia severity score excluding age (confusion, urea > 7 mmol/litre, respiratory rate ≥ 30 /min, blood pressure < 90 mm Hg systolic or ≤ 60 mm Hg diastolic), individual comorbidities, intravenous antibiotic use, nursing home residency and ICU admission. A similar model was used to examine the associations between combination antibiotic therapy and secondary outcomes, except ICU

admission was not included in the model when assessing need for MV, INS and ICU admission. Subgroup analysis according to pneumonia severity based on the CURB65 score was performed following adjustment for sex, individual comorbidities, intravenous antibiotic use and nursing home residency. Statistical significance was defined as a *p* value <0.05. Results are expressed as the OR with 95% CI.

RESULTS

There were 6312 patients in the national audit dataset; 1072 (17%) received an antibiotic other than a β -lactam or a β -lactam/macrolide combination, leaving 5240 for analysis. The commonest β -lactam antibiotic prescribed was co-amoxiclav (42.7%), followed by amoxicillin (23.3%), benzylpenicillin (17.6%), piperacillin with tazobactam (12.8%) and cephalosporins (3.6%). Combination therapy was prescribed in 3239 (61.8%) patients; the commonest macrolide prescribed was clarithromycin (96.1%), followed by erythromycin (3.7%) and azithromycin (0.2%). Narrow spectrum β -lactams (amoxicillin, bezylpenicillin) were more commonly prescribed in the combination compared with single-agent therapy group (44.2% vs 31.5%, *p*<0.001).

Patients who received combination therapy were significantly younger (median age 73 years (IQR 56–84) vs 76 years (IQR 59–85), *p*=0.001) and had significantly less coexisting stroke disease, renal disease and active malignancy compared with patients who received β -lactam therapy alone (see online supplementary table A). Of 4207 patients in whom data on residency were available, 194 (12.2%) in the β -lactam group were admitted from nursing or residential care compared with 222 (8.5%) in the combination therapy group (OR 0.66, 95% CI 0.54 to 0.81, *p*<0.001). ICU support (8.7% vs 6.8%; OR 1.3, 95% CI 1.05 to 1.6, *p*=0.009) and intravenous antibiotic use (87.0% vs 73.1%, *p*<0.001) were commoner in the combination therapy group.

Outcome measures

The overall 30-day IP death rate was 24.4% (1281/5240). On univariate analysis, 30-day IP death rate was lower in the combination versus single-therapy group (23.0% vs 26.8%; OR 0.81, 95% CI 0.72 to 0.93, *p*=0.001). On multivariate analysis, combination therapy remained significantly associated with lower 30-day IP death rate (adjusted OR 0.72, 95% CI 0.60 to

0.85, *p*<0.001) but not with secondary outcomes of ICU admission rate, need for MV, need for INS or 30-day readmission rate (adjusted OR=0.908, 95% CI 0.70 to 1.19, *p*=0.48) (table 1).

When stratified by pneumonia severity, combination therapy was significantly associated with lower 30-day IP death rate in moderate-severity CAP (adjusted OR 0.54, 95% CI 0.41 to 0.72, *p*<0.001) and high-severity CAP (adjusted OR 0.76, 95% CI 0.60 to 0.96, *p*=0.025), but not in low-severity CAP (table 1). Combination therapy was not significantly associated with secondary outcomes following stratification according to pneumonia severity.

DISCUSSION

This is the largest multicentre study of the 'real world' management of adult CAP in the UK. A striking finding is the relatively high death rate observed (24%). This is similar to results from a large database study (*n*>500 000) of UK hospital data comprising all admissions with pneumonia from 1997 to 2005 (30-day death rate 24.8–28.2%)⁵ and from a regional quality improvement programme of patients hospitalised with CAP (*n*=7352, in-hospital crude death rate 27%) (see references in online supplement). In contrast, the death rate from previous prospective cohort studies conducted in the UK has been lower (5–14%).¹ This discrepancy may be due to selection bias with fitter individuals being recruited into prospective cohort studies.

Combination therapy compared with β -lactam therapy alone was significantly associated with lower death rate after adjustment for demographic factors, pneumonia severity and treatment factors in patients with moderate-severity and high-severity CAP. Previous studies of CAP have also demonstrated a reduction in death rate associated with β -lactam/macrolide combination therapy compared with other antibiotic regimens (see references in online supplement). In particular, Tessmer *et al*² (*n*=1854) reported a significantly lower 14-day death rate only in patients with moderate-severity CAP (CURB65 score of 2) treated with β -lactam/macrolide combination antibiotics compared with single-agent β -lactam antibiotics. The much larger dataset of the current study confirms and extends these findings.

Mechanistic explanations for the superiority of β -lactam/macrolide combination therapy in the treatment of CAP include broader coverage of unidentified infection with atypical

Table 1 Multivariate analyses of the association between antibiotic therapy and clinical outcomes

Outcome measures	Total (n=5240)	β -lactam therapy (n=2001)	β -lactam/ macrolide combination therapy (n=3239)	Adjusted OR (95% CI)	p Value
30 day IP death rate	1281 (24.4)	536 (26.8)	745 (23.0)	0.72 (0.60 to 0.85)*	<0.001
ICU admission	419 (8)	136 (6.8)	282 (8.7)	0.94 (0.72 to 1.22)†	0.635
Need for MV	151 (2.9)	58 (2.9)	93 (2.9)	0.99 (0.71 to 1.38)†	0.508
Need for INS	130 (2.5)	42 (2.1)	88 (2.7)	0.87 (0.55 to 1.38)†	0.544
30-day IP death rate stratified by pneumonia severity					
Low severity (CURB65=0–1)	201/2247 (8.9)	95/908 (10.5)	106/1339 (7.9)	0.80 (0.56 to 1.16)‡	0.238
Moderate severity (CURB65=2)	370/1480 (25)	171/561 (30.5)	199/919 (21.7)	0.54 (0.41 to 0.72)‡	<0.001
High severity (CURB65≥3)	710/1513 (46.9)	270/532 (50.8)	440/981 (44.9)	0.76 (0.60 to 0.96)‡	0.025

Values given as n (%).

*OR adjusted for age, sex, binary variables within CURB65 excluding age (confusion, urea>7 mmol/l, respiratory rate ≥30/min, systolic blood pressure<90 mmHg or diastolic blood pressure ≤60 mmHg), individual comorbidities, intravenous antibiotic use, nursing home residency and ICU admission.

†OR adjusted for age, sex, binary variables within CURB65 excluding age (confusion, urea>7 mmol/l, respiratory rate ≥30/min, systolic blood pressure<90 mmHg or diastolic blood pressure ≤60 mmHg), individual comorbidities, intravenous antibiotic use and nursing home residency.

‡OR adjusted for sex, individual comorbidities, intravenous antibiotic use, nursing home residency and ICU admission.
ICU, intensive care unit; IP, inpatient; MV, mechanical ventilation; INS, inotropic support.

pathogens and macrolide-specific immunomodulatory, quorum sensing or alveolar epithelial effects.

A striking 37.9% of patients with moderate-severity CAP and 35.2% with high-severity CAP were not prescribed a macrolide, despite current UK guidance advocating combination therapy in these patients. This may reflect reluctance among physicians to prescribe macrolides in frailer patients, an interpretation supported by the observed differences between single and combination therapy groups in age, residency status and comorbid illnesses. Treatment restriction in frailer patients, such as a higher threshold for ICU admission, may have contributed to bias in the results. These confounders were adjusted for in the multivariate analyses; however, residual confounding cannot be completely discounted. Differences in β -lactam antibiotic coverage between the groups are unlikely to explain the observed treatment effect; narrow spectrum β -lactam antibiotic use was commoner in the combination therapy group.

Other limitations of the study include the absence of additional details related to antibiotic therapy (including prior antibiotic administration and duration of therapy) and absence of information about other aspects of care (such as the use of supplemental oxygen or venous thromboembolic prophylaxis). Therefore, the possibility that combination antibiotic therapy is simply a surrogate for other or multiple aspects of better quality care could not be explored in this study.

Given the observed size of effect and the consistency of results across many studies, it is likely that the association of combination therapy with reduced death rate in moderate-severity and high-severity CAP is a true effect, though the true effect size may be smaller than that observed in this study. An adequately powered randomised controlled trial of β -lactam/

macrolide combination therapy versus β -lactam single-agent therapy in patients with moderate-severity and high-severity CAP would valuably inform this issue. In the meantime, the available evidence indicates that efforts should be made to improve guideline implementation and adherence in clinical practice, especially given the current unsystematic use of combination therapy highlighted by this study.

Acknowledgements The authors would like to thank the British Thoracic Society audit team, including Sally Welham, Chris Routh, Kerry Reid and Christine Bucknall, for their invaluable efforts in conducting the audit. This paper has been prepared by the authors on behalf of the British Thoracic Society, and the efforts by clinicians across the UK in data collection and participation in this audit are gratefully acknowledged.

Contributors This paper has been prepared by the authors on behalf of the British Thoracic Society.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- 1 Lim WS, Baudouin SV, George RC, *et al.* British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax* 2009;64:iii1–iii55.
- 2 Tessmer A, Welte T, Martus P, *et al.* Impact of intravenous beta-lactam/macrolide versus beta-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. *J Antimicrob Chemother* 2009;63:1025–33.
- 3 Asadi L, Sligl WI, Eurich DT, *et al.* Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. *Clin Infect Dis* 2012;55:371–80.
- 4 Lim WS, Woodhead M. British Thoracic Society adult community acquired pneumonia audit 2009/10. *Thorax* 2011;66:548–9.
- 5 Trotter CL, Stuart JM, George R, *et al.* Increasing hospital admissions for pneumonia, England. *Emerg Infect Dis* 2008;14:727–33.

SUPPLEMENTARY DETAILS (FOR ONLINE REPOSITORY)

Other discussion points

1. It would be desirable to know the percentage of patients captured in the study as a proportion of all patients hospitalised with CAP at study sites during the study period. However, it is extremely difficult to obtain a true denominator due to inaccuracies in current hospital coding systems – estimates from various local audits indicate that up to 50% of episodes coded as CAP are inaccurate. For this audit, Trusts were asked to submit data on all patients admitted with CAP within the audit period. Some Trusts had prospective audit systems in place, reliant on the identification of relevant patients at the time of hospital admission, while other Trusts retrieved medical notes from all patients with a discharge code for pneumonia and screened for eligibility. Each Trust may have missed a proportion of patients admitted with CAP during the study period. However, overall, given the large dataset and the number of institutions involved, we do not anticipate any systematic bias in one particular direction in terms of case selection.
2. Narrow spectrum beta-lactams, such as amoxicillin or benzylpenicillin, differ in terms of antibiotic coverage of Gram negative infections compared to broad spectrum beta-lactams, such as co-amoxiclav. However, Gram negative organisms are seldom implicated (<2%) in patients hospitalised with CAP in the UK. Furthermore, narrow spectrum beta-lactams were more commonly prescribed in the combination therapy group compared to the single agent therapy group. Therefore, it is unlikely that superior antibiotic coverage of such infections, or co-infections, accounts for the differences observed.
3. Antibiotics prior to hospital admission are associated with better clinical outcomes. Therefore, if pre-treated patients were more likely to receive combination therapy, this may partially account for the observed differences in mortality. Unfortunately, data on pre-hospital treatment were not available to test this hypothesis. However, in most clinical practice in the UK, the decision whether to give combination empirical antibiotic therapy at the time of hospital admission is not dependent on pre-hospital treatment. Therefore, it seems unlikely that there would be a strong association between pre-treatment and empirical combination therapy, though this cannot be discounted.

Supplementary Table A

Clinical characteristics of study cohort (n=5240)

	Beta-lactam therapy (n=2001)	Beta-lactam/macrolide combination therapy (n=3239)	p value
Age*	76 (59-85)	73 (56-84)	0.001
Male	967 (48.3)	1646 (50.8)	0.042
CCF	162 (8.1)	234 (7.2)	0.135
Stroke disease	208 (10.4)	288 (8.9)	0.04
Liver disease	30 (1.5)	35 (1.1)	0.115
Renal disease	154 (7.7)	197 (6.1)	0.014
Active Malignancy	166 (8.3)	203 (6.3)	0.003
COPD	397 (19.8)	648 (20.0)	0.457
IV antibiotic use	1463(73.1)	2817(87.0)	<0.001
ICU admission	136(6.8)	282(8.7)	0.009
Need for MV	58(2.9)	93(2.9)	0.508
Need for INS	42(2.1)	88(2.7)	0.095
Median LOS*†	5(2-10)	6(3-11)	0.094
Time to death*†	5(2-10)	5(2-11)	0.550
CURB65 0-1	908(45.4)	1339(41.3)	0.002
CURB65 2	561(28.0)	919(28.4)	0.409
CURB65 3-5	532(26.6)	981(30.3)	0.002

IQR-Inter-quartile range, CCF-Congestive cardiac failure, COPD-Chronic obstructive pulmonary disease, ICU-Intensive care unit, MV-mechanical ventilation, INS-Inotropic support, LOS-length of stay

All values given as n(%) unless stated otherwise

*Values given as median(IQR)

†Measured in number of days

Supplementary Table B

Antibiotics other than a beta-lactam or beta-lactam/macrolide combination prescribed for patients in the national dataset (n=1072)

Antibiotic	n	%
Macrolide	552	51.5
Tetracyclines	252	23.5
Fluoroquinolones	114	10.6
Sulphonamides	21	2.0
Chloramphenicol	26	2.4
Aminoglycosides	16	1.5
Vancomycin/Teicoplanin	69	6.4
Metronidazole	8	0.7
Rifampicin	2	0.2
No antibiotic data available	63	5.9

Supplementary References

- Kent, Surrey and Sussex NHS Trust-What a difference a year makes (2010-2011); Available from:http://www.enhancingqualitycollaborative.nhs.uk/index.php?option=com_docman&task=doc_download&gid=1&Itemid=19 (accessed 31/05/2012).
- Vázquez EG, Mensa J, Martínez JA, et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. *Eur J Clin Microbiol Infect Dis* 2005;24:190-5.
- Houck PM, MacLehose RF, Niederman MS, et al. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 Western states 1993, 1995, and 1997. *Chest* 2001;119:1420-6.
- Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. *Arch Intern Med* 1999;159:2562-72.
- Martínez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a b-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. *Clin Infect Dis*;36:389-95.
- Weiss K, Low D, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic streptococcus pneumoniae pneumonia in adults. *Can Respir J* 2004;11(8):589-93.
- Paul M, Nielsen AD, Gafter-Gvili A, et al. The need for macrolides in hospitalised community-acquired pneumonia: Propensity analysis. *Eur Respir J* 2007;30:525-31.
- Aspa J, Rajas O, Rodriguez de Castro F, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. *Eur Respir J* 2006;27:1010-9.
- Blasi F, Iori I, Bulfoni A, et al. Can CAP guideline adherence improve patient outcome in internal medicine departments? *Eur Respir J* 2008;32:902-10.
- Schouten JA, Hulscher MEJL, Trap-Liefers J, et al. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: A cluster-randomized, controlled trial. *Clin Infect Dis* 2007;44:931-41.
- Sharpe BA. Guideline-recommended antibiotics in community-acquired pneumonia: Not perfect, but good. *Arch Intern Med* 2009;169(16):1462-4.
- Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. *Intensive Care Med* 2010;36:612-20.
- Metersky ML, Ma A, Houck PM, et al. Antibiotics for bacteremic pneumonia improved outcomes with macrolides but not fluoroquinolones. *Chest* 2007;131:466-73.
- Livermore DM, Reynolds R, Stephens P, et al. Trends in penicillin and macrolide resistance among pneumococci in the UK and the Republic of Ireland in relation to antibiotic sales to pharmacies and dispensing doctors. *Int J Antimicrob Agents* 2006;28:273-9.
- Guillota L, Tabarya O, Nathana N, et al. Macrolides: New therapeutic perspectives in lung diseases. *Int J Biochem Cell Biol* 2011;43:1241-6.
- Wise MP, Williams DW, Lewis MA, et al. Macrolides and community-acquired pneumonia: Is quorum sensing the key? *Crit Care* 2010;14(181):1-3.

- Healy DP. Macrolide immunomodulation of chronic respiratory diseases. *Curr Infect Dis Rep* 2007;9(1):7-13.
- Bartlett JG. Is activity against “atypical” pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy. *Clin Infect Dis* 2008;47:S232-6.
- Robenshtok E, Shefet D, Gafer-Gvili A, et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. *Cochrane Database Syst Rev* 2008(1). Epub 14 April 2010.